

Kålsängsgränd 10 D
753 19 Uppsala
Sweden

www.lobsor.com
info@lobsor.com
+46 18 444 46 02

Press Release

Uppsala, April 9, 2019

Swedish Dental and Pharmaceutical Benefits Agency (TLV) authorizes reimbursement of Lecigon[®], an intestinal gel, for Advanced Parkinson's Disease

Lobsor Pharmaceuticals AB, a privately held Swedish company today reported that following Swedish MPA market approval in October 2018, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) has included Lecigon[®] on Sweden's list of reimbursed drugs. This marks a major milestone as Sweden becomes the first country to offer patients this new therapeutic system for symptomatic treatment of Advanced Parkinson's disease (APD). Roger Bolsöy, CEO of Lobsor said, "The new treatment system includes a new formulation using three substances already approved for the treatment of APD, as well as a lightweight delivery pump. Furthermore, the pivotal clinical trial with Lecigon[®] showed the same clinical outcome as current advanced levodopa therapy but with a significantly reduced dose." "We now intend to obtain further market approvals and introduce Lecigon[®] into carefully selected markets throughout Europe over the next 24 months," continues Bolsöy.

This reimbursement applies to treatment of Advanced Parkinson's disease*.

For further information, please contact:

Ulf Rosén, Founder and Chairman of Lobsor Holding AB

Telephone: +46 70 686 29 16

Email: ulf.rosen@lobsor.com

** Indication: Severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of anti-Parkinsonian medicinal products have not given satisfactory results.*

###

Notes to editors

About Parkinson's disease

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. PD is age-related and affects nearly 1% of the population over 60 years and 5% over 85 years, with high health, social, and economic impact. PD is a progressive disorder in which dopaminergic neurons are degenerated. Dopamine deficiency at (striatal) receptor sites presents as both motor and non-motor disability such as bradykinesia (slow movement), tremor, rigidity (stiffness), postural instability, depression, and sleep disturbance. The symptoms vary between patients and the number of symptoms and the severity tend to increase over time, creating a more complex clinical picture. Parkinson's disease, particularly in its advanced stage is a devastating disease with symptoms including uncontrollable shaking or tremor, lack of coordination and speaking difficulties. In addition, erratic gastric functioning is an important part of making patients refractive to oral treatment and techniques are used to bypass the stomach by introducing a small tube via the abdomen wall for pharmaceutical infusion into the duodenum. An estimated seven to ten million people worldwide are living with Parkinson's disease and for most patients their disease will eventually reach the advanced stage.

About TLV

The Dental and Pharmaceutical Benefits Agency, TLV, is a central government agency whose remit is to determine whether a pharmaceutical product, medical device or dental care procedure shall be subsidized by the state. It also determines retail margins for all pharmacies in Sweden, regulates the substitution of medicines at the pharmacies and supervises certain areas of the pharmaceutical market.

About Lobsor

Lobsor Pharmaceuticals is a privately held company based in Uppsala, Sweden founded late 2013. The Lobsor team has substantial previous experience from the treatment of Parkinson's disease in advanced stages especially continuous infusion of levodopa into the small intestine via a pump. Both founders had leading executive roles in NeoPharma during the development and commercialization of Duodopa. Lobsor's near-term focus is to obtain market authorization in the Nordic countries and key markets in Europe. A newly formed US based company, Intrance Medical Systems Inc. is responsible for commercialization in the US and Canada. Several interactions have already been made with the FDA.

About Lecigon

The new patented treatment is a pharmaceutical gel formulation containing a combination of levodopa/carbidopa and entacapone in a 50 ml pre-filled container for infusion continuously into the small intestine. Furthermore, the pivotal clinical trial with Lecigon® showed the same clinical outcome as current advanced levodopa therapy but with a significantly reduced dose. The treatment system includes a newly developed, small and wearable pump weighing only 134 grams. The pump can be carried under the clothing and thanks to its low weight, neck- and shoulder pain can likely be avoided. An illuminated screen on the pump facilitates switching between pre-set doses, providing a feeling of security and trust both in daylight and if it is dark.

Lecigon has an approved shelf-life of 24 hours in room temperature. Thus, patients can prepare the system in the evening and store it beside the bed before going to sleep and start the treatment in the morning while they are in bed, thus avoiding the need to get it from the fridge when they may be in a rigid condition with increased risk of falling. With the 24-hour shelf-life, it is also possible to continue to use a cartridge the next day, something

particularly useful for high dose patients, thus avoiding unnecessary waist. The lower levodopa dose required is due to increased bioavailability of levodopa which prolongs the half-life of levodopa. As a consequence, the time before symptoms occur after the pump is switched off is probably prolonged and will give the patient more time off-treatment when e.g. taking a shower